## Clinical Research Trials December 30, 2019

## John T. Vucurevich Cancer Care Institute

rain	Trial Title	ClinicalTrials.gov Link
	Phase III Intergroup Study of Radiotherapy vs Temozolomide Alone vs Radiotherapy with Concomitant and	
Anaplastic Glioma (No577)	Adjuvant Temozolomide for Patient with 1p/19q Codeleted Anaplastic Glioma	https://clinicaltrials.gov/ct2/show/NCT00887146?id=n0577&rank=1
Breast	Trial Title	ClinicalTrials.gov Link
	A Randomized Phase III Double Blinded Placebo Controlled Trial Of Aspirin As Adjuvant Therapy For HER2	
Node (+) (A011502)	Negative Breast Cancer: The ABC Trial.	https://clinicaltrials.gov/ct2/show/NCT02927249?id=a011502&rank=1
Metastatic /Advanced / Refractory	A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in	
(A171601)	Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer	https://clinicaltrials.gov/ct2/show/NCT03633331?id=a171601&rank=1
	A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed	
Adjuvant/Node+ or HR Node- Triple	by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High Risk Node NegativeTriple Negative	
Negative (BR003)	Invasive Cancer	https://clinicaltrials.gov/ct2/show/NCT02488967?id=br003&rank=1
	A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant	
	Therapy for Triple Receptor- Negative Breast Cancer with >/=1 CM Residual Invasive Cancer or Positive Lymph	
Neo-Adjuvant Triple Negative (\$1418)	Nodes (ypN+) after Neoadjuvant Chemotherapy	https://clinicaltrials.gov/ct2/show/NCT02954874?id=s1418&rank=1
Gastrointestinal	Trial Title	ClinicalTrials.gov Link
	Randomized Trial of FOLFOX Alone or in Combined with Atezolizumab as Adjuvant Therapy for Patients with	<u> </u>
Colon - Adjuvant / Resected (A021502)	Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instabilitu (ATOMIC)	https://clinicaltrials.gov/ct2/show/NCT02912559?id=a021502&rank=1
enitourinary	Trial Title	ClinicalTrials,gov Link
-	PD-Inhibitor (Nivolumab) and Ipilimumab followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab:	<u> </u>
Metastatic Renal Cell (Ao31704)	A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE).	https://clinicaltrials.gov/ct2/show/NCT03793166?id=a031704&rank=1
	Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without	
Recurrent Prostate (GUoo6)	Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)	https://clinicaltrials.gov/ct2/show/NCT03371719?id=gu006&rank=1
ynecologic	Trial Title	ClinicalTrials.gov Link
	A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or	
Ovarian / Peritoneal / Fallopian	Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -	
Tube/Endometrial (GY005)	Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)	https://clinicaltrials.gov/ct2/show/NCT02502266?id=gy005&rank=2
	A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus	
Ovarian / Peritoneal / Fallopian	Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal	
Tube/Endometrial (GY009)	Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer	https://clinicaltrials.gov/ct2/show/NCT02839707?id=gy009&rank=1
lematologic	Trial Title	ClinicalTrials.gov Link
Myelodyplastic Syndrome and		
Symptomatic Anemia (NHLBI-MDS)	The National Myelodysplastic Syndromes (MDS) Study	https://clinicaltrials.gov/ct2/show/NCT02775383?id=nhlbi-mds&rank=1
ung	Trial Title	ClinicalTrials.gov Link
Limited Stage Small Cell (LU005)	A Phase II/III Randomized Study of Chemoradiation vs. Chemoradiation plus Atezolizumab.	https://clinicaltrials.gov/ct2/show/NCT03811002?id=lu005&rank=1
ymptom Management/Other	Trial Title	ClinicalTrials.gov Link
ymptom wanagemenyother	Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors	https://clinicaltrials.gov/ct2/show/NCT03662204?id=2018-01&rank=9
Biomarkers (2018-01)		
Biomarkers (2018-01)	· · · · · · · · · · · · · · · · · · ·	https://clinicaltrials.gov/ct2/show/NCT03727009?id=2018-02&rank=4
Biomarkers (2018-01) Biomarkers (2018-02)	Blood Sample Collection to Evaluate Biomarkers in Subjects with Hematologic Malignancies	https://clinicaltrials.gov/ct2/show/NCT03727009?id=2018-02&rank=4
Biomarkers (2018-01) Biomarkers (2018-02) Symptom Reporting (AFT-39/PRO-	Blood Sample Collection to Evaluate Biomarkers in Subjects with Hematologic Malignancies	
Biomarkers (2018-01) Biomarkers (2018-02)	· · · · · · · · · · · · · · · · · · ·	https://clinicaltrials.gov/ct2/show/NCT03727009?id=2018-02&rank=4  https://clinicaltrials.gov/ct2/show/NCT03249090?id=aft-39&rank=1

3/9/20 1 of 1